About the Team
Genesis Research offers ML Researchers & Engineers the opportunity to rapidly accelerate the creation of previously impossible medicines. Our work benefits from diverse backgrounds and strong ML expertise because going after undruggable targets requires new ideas.
We are seeking curious explorers who seek the space to try new things with ample support and a path to grow. You’ll bring your ML expertise to the table, collaborating with world class chemists and biologists to manifest the digital domain in the physical world. The result? New treatments for devastating diseases.
The Role
The Head of Machine Learning Research will lead and shape the Machine Learning Research group, driving the development of innovative models and methodologies for drug discovery. Reporting to the CEO & Founder, this leadership role involves overseeing teams of ML Research Scientists and Engineers, fostering a culture of collaboration and scientific excellence, and partnering cross-functionally to deliver state-of-the-art machine learning solutions.
This position combines strategic vision, technical leadership, and team mentorship to ensure Genesis Therapeutics remains at the forefront of machine learning for drug discovery.
Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.
Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.
The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has three AI platform collaborations across a range of therapeutic areas, with Gilead Sciences, Eli Lilly, and Genentech.
We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures.
Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.